Device assessed activity behaviours in patients with indwelling pleural catheter: A sub-study of the Australasian Malignant PLeural Effusion (AMPLE)-2 randomized trial

Carolyn J. Peddle-McIntyre, Sanjeevan Muruganandan, Joanne McVeigh, Deirdre B. Fitzgerald, Leon Straker, Robert U. Newton, Kevin Murray, Yun Chor Gary Lee

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background and ObjectiveDevice-assessed activity behaviours are a novel measure for comparing intervention outcomes in patients with malignant pleural effusion (MPE). Australasian Malignant PLeural Effusion (AMPLE)-2 was a multi-centre clinical trial where participants with MPE treated with an indwelling pleural catheter were randomized to daily (DD) or symptom-guided (SGD) drainage for 60-days. Our aim was to describe activity behaviour patterns in MPE patients, explore the impact of drainage regimen on activity behaviours and examine associations between activity behaviours and quality of life (QoL). MethodsFollowing randomization to DD or SGD, participants enrolled at the lead site (Perth) completed accelerometry assessment. This was repeated monthly for 5-months. Activity behaviour outcomes were calculated as percent of daily waking-wear time and compared between groups (Mann-Whitney U test; Median [IQR]). Correlations between activity behaviour outcomes and QoL were examined. ResultsForty-one (91%) participants provided >= 1 valid accelerometry assessment (DDn = 20, SGD n = 21). Participants spent a large proportion of waking hours sedentary (72%-74% across timepoints), and very little time in moderate-to-vigorous physical activity (

Original languageEnglish
Pages (from-to)561-570
Number of pages10
JournalRespirology
Volume28
Issue number6
Early online dateJan 2023
DOIs
Publication statusPublished - Jun 2023

Fingerprint

Dive into the research topics of 'Device assessed activity behaviours in patients with indwelling pleural catheter: A sub-study of the Australasian Malignant PLeural Effusion (AMPLE)-2 randomized trial'. Together they form a unique fingerprint.

Cite this